Efficacy and Comparability of Thiazide-type Diuretics

Slides:

Advertisements

Similar presentations

CR-1 ATACAND ® (candesartan cilexetil) Cardiovascular and Renal Drugs Advisory Committee Bethesda, Maryland July 18, 2002 C.

Advertisements

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

Valsartan Antihypertensive Long-Term Use Evaluation Results

ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.

Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.

The Rationale for Initiating Therapy with Fixed-Dose Combinations in Hypertension Thomas D. Giles, M.D. Tulane University School of Medicine New Orleans,

Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.

1 The Study of Trandolapril- verapamil And insulin Resistance STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP.

New concept – no traditional combination LODOZ contains Bisoprolol and Hydrochlorothiazide in subtherapeutic dosages: - Bisoprolol 2.5 mg (= half / quarter.

Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid- lowering Treatment to Prevent Heart.

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

1 U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Major Outcomes in High Risk Hypertensive.

Comparison of Blood Pressure Lowering with Hydrochlorothiazide and Chlorthalidone Kurt A. Wargo, Pharm.D., BCPS, Thomas M. English, Ph.D., Anna J. Aaron,

Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.

Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):

1 Can One Evaluate An Outcomes Claim Based On An Active Controlled Study? Pfizer Response Cardiovascular and Renal Drugs Advisory Committee Rockville,

A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.

CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Thiazide-Like/Calcium Channel Blocker (CCB) Agents: A Major Combination for Hypertension Management Safar M, Blacher J. Am J Cardiovasc Drugs. 2014; DOI.

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.

HvC Comparative Effectiveness Project Groups 5 and 6

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

Thiazide diuretics, Potassium, and the Development of Diabetes A Quantitative Review Hypertension2006_219.

A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

CSM-1 Patients With and Without Obesity LSM Difference and 95% CI in BP (230, 231 Pooled) † Diastolic BP Overall (N = 1,191) Obese.

Int J Clin Pract, December 2013, 67, 12,

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.

Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

From ESH 2016 | POS 7D: Jan Rosa, MD

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Vanguard Phase Results for the Blood Pressure Component

Flowchart of participants

Neal B, et al. Diabetes Care 2015;38:403–411

Aliskiren and Valsartan for Antihypertensive Therapy Trial

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

Hypertension Guidelines

ALLHAT: What Outcomes Would Have Been Expected?

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

These slides highlight a report based on original presentations at the 24th Meeting of the French Society of Arterial Hypertension (SFHTA) in Paris, France,

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

Health and Human Services National Heart, Lung, and Blood Institute

End point Net change with soy supplements vs control (95% CI) p

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Managing Blood Pressure

End point Valsartan Valsartan+HCTZ p

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Role of - Azilsartan - Azilsartan/chlorthalidone

Presentation transcript:

Efficacy and Comparability of Thiazide-type Diuretics ALLHAT Efficacy and Comparability of Thiazide-type Diuretics

Chlorthalidone vs. Hydrochlorthiazide (HCTZ)/ Triamterene in Hypertensives Chlorthalidone (50 mg/day) was compared to HCTZ plus triamterene (25/50 and 50/100 mg/day) in 126 patients with DBP 90-115 mm Hg over an 8-week treatment period in a 3-arm double-blind, placebo-controlled randomized trial. Clark EC, et al. Southern Med J. 1979;72:798-802.

Chlorthalidone vs. Hydrochlorthiazide (HCTZ)/ Triamterene in Hypertensives mmHg All drugs produced a significant reduction in BP from placebo sig. lower than H25/T50 Clark EC, et al. Southern Med J. 1979;72:798-802.

Chlorthalidone vs. Hydrochlorthiazide (HCTZ)/ Triamterene in Hypertensives All three regimens significantly reduced SBP and DBP at every week of therapy Significant BP differences between chlorthalidone and HCTZ/triamterene (25/50 mg) were found, but not for chlorthalidone compared to HCTZ/triamterene (50/100 mg) or between the two HCTZ formulations Clark EC, et al. Southern Med J. 1979;72:798-802.

Chlorthalidone vs. Hydrochlorthiazide (HCTZ)/ Triamterene in Hypertensives Once daily administration of HCTZ/triamterene was effective in patients with diastolic hypertension, although HCTZ/triamterene at the lower dose (25/50 mg) was less effective than 50 mg of chlorthalidone. Clark EC, et al. Southern Med J. 1979;72:798-802.

Dose-Response to Chlorthalidone in Patients with Stage 1 Hypertension 4 doses of chlorthalidone (12.5, 25, 50, 75 mg) were compared to placebo for 12 weeks of treatment in 100 patients with DBP of 90-109 mm Hg. Success was defined as DBP <90 mm Hg and/or decrease of 10 mm Hg or more at the final visit. Materson BJ, et al. Clin Pharmacol Ther. 1978;24:192-198.

Dose-Response to Chlorthalidone in Patients with Stage 1 Hypertension mmHg sig. reduction compared to placebo Materson BJ, et al. Clin Pharmacol Ther. 1978;24:192-198.

Dose-Response to Chlorthalidone in Patients with Stage 1 Hypertension Although chlorthalidone 12.5 mg was superior to placebo in reducing supine and standing systolic BP, there were no differences in standing systolic BP for doses between 25 and 75 mg. Diastolic success rates were not significantly different among all active doses: 45% (12.5 mg), 35% (25 mg), 41% (50 mg), and 42% (75 mg) The decline in serum potassium was worse than placebo only with the 50 and 75 mg doses No changes in serum uric acid, serum glucose, or serum sodium were observed. Materson BJ, et al. Clin Pharmacol Ther. 1978;24:192-198.

Dose-Response to Chlorthalidone in Patients with Stage 1 Hypertension 25 mg of chlorthalidone was as effective as 50 and 75 mg doses for treatment of hypertension, with fewer adverse effects. 12.5 mg of chlorthalidone was also effective, although the decline in blood pressure was smaller than that achieved by the larger doses. Materson BJ, et al. Clin Pharmacol Ther. 1978;24:192-198.

Chlorthalidone vs. Hydrochlorthiazide (HCTZ) in Moderate Hypertensives Chlorthalidone (50 mg once per day) was compared to hydrochlorthiazide (50 mg twice per day) 55 patients DBP 100-120 mm Hg 4 week treatment period Finnerty FA. Angiology. 1976;27:738-744.

Chlorthalidone 50 mg vs. HCTZ 50 mg BID in Hypertensives with DBP 100-120 mm Hg SBP DBP Finnerty FA. Angiology. 1976;27:738-744.

Chlorthalidone vs. HCTZ in Moderate Hypertensives Both treatment groups experienced a significant reduction in SBP and DBP during treatment, with no significant differences between groups. Near normotensive mean DBP levels were achieved by both groups within two weeks, and were sustained for the duration of the study. Serum potassium declined significantly only in the HCTZ group. No other significant changes were found in serum sodium, serum creatinine, serum cholesterol, or fasting glucose. Finnerty FA. Angiology. 1976;27:738-744.

Chlorthalidone vs. HCTZ in Moderate Hypertensives Chlorthalidone 50 mg QD and HCTZ 50 mg BID were equally effective in reducing BP. Chlorthalidone was associated with fewer side-effects when given at ½ the HCTZ dose. Finnerty FA. Angiology. 1976;27:738-744.

Pharmacokinetic and Pharmacodynamic Comparisons of HCTZ and Chlorthalidone Drug Onset, h Peak, h Half-Life, h Duration, h HCTZ 2 4-6 6-9 (Single dose) 12 (Single dose) 8-15 (Long-term dose) 16-24 (Long-term dosing) Chlorthalidone 2-3 2-6 40 (Single dose) 24-48 (Single dose) 45-60 (Long-term dosing) 48-72 (Long term dosing) Carter BL. Hypertension 2004.

ALLHAT Conclusions (I) In these studies chlorthalidone 25 mg/d or HCTZ 50 mg/d lowered BP as well as higher doses with fewer adverse effects. Lower doses (chlorthalidone 12.5 mg or HCTZ 25 mg) were effective in lowering BP, but less so than chlorthalidone 25 mg or HCTZ 50 mg. Chlorthalidone has a considerably longer duration of action than HCTZ.

ALLHAT Conclusions (II) The ideal dose-comparison trial of HCTZ versus chlorthalidone has not yet been conducted. Low-moderate dose diuretics are consistent in showing a reduction of events in morbidity and mortality trials.